In silico prediction of human serum albumin binding for drug leads

Bibliography

• Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-15
   PubMed Web of Science ®Google Scholar
• Gaviraghi G, Barnaby RJ, Pellegatti M. Pharmacokinetic challenges in lead optimization. In: Testa B, van de Waterbeemd H, Folkers G, Guy R, editors. Pharmacokinetic optimization in drug research. Verlag Helvetica Chimica Acta, Zürich; 2001. p. 3-14
   Google Scholar
• Testa B, Vistoli G, Pedretti A. Musings on ADME predictions and structure - activity relations. Chem Biodiver 2005;2:1411-27
   PubMed Web of Science ®Google Scholar
• Rogge MC, Taft DR. Preclinical drug development. In: Swarbrick J, editor. Drugs and the pharmaceutical sciences. Volume 187. Informa Healthcare, USA; 2010
   Google Scholar
• Smith DA, van de Waterbeemd H. Pharmacokinetics and metabolism in early drug discovery. Curr Opin Chem Biol 1999;4:373-8
   Web of Science ®Google Scholar
• Hollósy F, Valkó K, Hersey A, Estimation of volume of distribution in humans from high throughput HPLC-based measurements of human serum albumin binding and immobilized artificial membrane. J Med Chem 2006;49:6958-71
   PubMed Web of Science ®Google Scholar
• Ito K, Iwatsubo T, Kanamitsu S, Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism together with binding and transport. Ann Rev Pharmacol Toxicol 1998;38:461-99
   PubMed Web of Science ®Google Scholar
• Rowley M, Kulagowski JJ, Watt AP, Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists. J Med Chem 1997;40:4053-68
   PubMed Web of Science ®Google Scholar
• Rolan PE. Plasma protein binding displacement interactions—Why are they regarded as clinically important? Br J Clin Pharmacol 1994;37:125-8
   PubMed Web of Science ®Google Scholar
• Hage DS. High performance affinity chromatography: a powerful tool for studying serum protein binding. J Chromatogr B 2002;768:3-30
   PubMed Web of Science ®Google Scholar
• Noctor TAG, Wainer IW, Hage DS. Allosteric and competitive displacement of drugs from human serum albumin by octanoic acid, as revealed by high-performance liquid affinity chromatography, on a human serum albumin-based stationary phase. J Chromatogr Biomed Appl 1992;577:305-15
   Web of Science ®Google Scholar
• Benet LZ, Hoener B. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002;71:115-21
   PubMed Web of Science ®Google Scholar
• Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov 2010;9:929-39
   PubMed Web of Science ®Google Scholar
• Stamler JS, Jaraki O, Osborne J, Nitric oxide circulates in mammalian plasma primarily as a S-nitroso adduct of serum albumin. Proc Natl Acad Sci USA 1992;89:7674-7
   PubMed Web of Science ®Google Scholar
• Torres E, Aburto J. Chloroperoxidase-catalyzed oxidation of 4,6-dimethyldibenzothiophene as dimer complexes: evidence for kinetic cooperativity. Arch Biochem Biophys 2005;437:224-32
   PubMed Web of Science ®Google Scholar
• Bertucci C, Andrisano V, Gotti R, Cavrini VJ. Use of an immobilised human serum albumin HPLC column as a probe of drug-protein interactions: the reversible binding of valproate. J Chromatogr B 2002;768:147-55
   PubMed Web of Science ®Google Scholar
• Nobeli I, Favia AD, Thornton JM. Protein promiscuity and its implications for biotechnology. Nat Biotechnol 2009;27:157-67
   PubMed Web of Science ®Google Scholar
• Leo A, Hansch C, Elkins D. Partition coefficients and their uses. Chem Rev 1971;71:525-616
   Web of Science ®Google Scholar
• Lejon S, Frick IM, Björck L, Crystal structure and biological implications of a bacterial albumin binding module in complex with human serum albumin. J Biol Chem 2004;279:42924-8
   PubMed Web of Science ®Google Scholar
• Curry S, Brick P, Franks NP. Fatty acid binding to human serum albumin: new insights from crystallographic studies. Biochim Biophys Acta 1999;1441:131-40
   PubMed Web of Science ®Google Scholar
• Bujacz A. Structures of bovine, equine and leporine serum albumin. Acta Crystallogr D Biol Crystallogr 2012;68:1278-89
   PubMed Web of Science ®Google Scholar
• Carter DC, Ho JX. Structure of serum albumin. Adv Protein Chem 1994;45:153-203
   PubMedGoogle Scholar
• Deeb O, Rosales-Hernández MC, Gómez-Castro C, Exploration of human serum albumin binding sites by docking and molecular dynamics flexible ligand-protein interactions. Biopolymers 2010;93:161-70
   PubMed Web of Science ®Google Scholar
• Kratochwil NA, Huber W, Müller F, Predicting plasma protein binding of drugs: a new approach. Biochem Pharmacol 2002;64:1355-74
   PubMed Web of Science ®Google Scholar
• Petitpas I, Bhattacharya AA, Twine S, Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I. J Biol Chem 2001;276:22804-9
   PubMed Web of Science ®Google Scholar
• Sudlow G, Birkett DJ, Wade DN. The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol 1975;11:824-32
   PubMed Web of Science ®Google Scholar
• Sjoholm I, Ekman B, Kober A, Binding of drugs to human serum albumin:XI. The specificity of three binding sites as studied albumin immobilized in microparticles. Mol Pharmacol 1979;16:767-77
   PubMed Web of Science ®Google Scholar
• Petitpas I, Petersen CE, Ha CE, Structural basis of albumin-thyroxine interactions and familial dysalbuminemic hyperthyroxinemia. Proc Natl Acad Sci USA 2003;100:6440-5
   PubMed Web of Science ®Google Scholar
• Ghuman J, Zunszain PA, Petitpas I, Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol 2005;353:38-52
   PubMed Web of Science ®Google Scholar
• Peters T. All about albumin: biochemistry, genetics and medical applications. Academic Press, San Diego; 1995
   Google Scholar
• Curry S. Lessons from the crystallographic analysis of small molecule binding to human serum albumin. Drug Metab Pharmacokinet 2009;24:342-57
   PubMed Web of Science ®Google Scholar
• Kwong TC. Free drug measurements: methodology and clinical significance. Clin Chim Acta 1985;151:193-216
   PubMed Web of Science ®Google Scholar
• Barre J, Didey F, Delion F, Tillement JP. Problems in therapeutic drug monitoring: free drug level monitoring. Ther Drug Monit 1988;10:133-43
   PubMed Web of Science ®Google Scholar
• Chaiken IM. editor. Analytical affinity chromatography. CRC Press, Boca Raton, FL; 1987
   Google Scholar
• Noctor TAG, Pham CD, Kaliszan R, Wainer IW. Stereochemical aspects of benzodiazepine binding to human serum albumin. I. Enantioselective high performance liquid affinity chromatographic examination of chiral and achiral binding interactions between 1,4-benzodiazepines and human serum albumin. Mol Pharm 1992;42:506-11
   PubMed Web of Science ®Google Scholar
• Nakano NI, Shimamori Y, Yamaguchi S. Binding capacities of human serum albumin monomer and dimer by continuous frontal affinity chromatography. J Chromatogr 1982;237:225-32
   PubMed Web of Science ®Google Scholar
• Ashton DS, Beddell CR, Cockerill GS, Binding measurements of indolocarbazole derivatives to immobilised human serum albumin by high-performance liquid chromatography. J Chromatogr B 1996;677:194-8
   PubMed Web of Science ®Google Scholar
• Chrysanthakopoulos M, Giaginis C, Tsantili-Kakoulidou A. Retention of structurally diverse drugs in human serum albumin chromatography and its potential to simulate plasma protein binding. J Chromatogr A 2010;1217:5761-8
   PubMed Web of Science ®Google Scholar
• Fournier T, Medjoubi-N N, Porquet D. Alpha-1-acid glycoprotein. Biochim Biophys Acta 2000;1482:157-71
   PubMed Web of Science ®Google Scholar
• Huang Z. Effect of Alpha-1-Acid Glycoprotein binding on pharmacokinetics and Pharmacodynamics. Curr Drug Metab 2012; Epub ahead of print
   Web of Science ®Google Scholar
• Hervé F, Caron G, Duché JC, Ligand specificity of the genetic variants of human alpha-1-acid glycoprotein. Generation of a 3D-QSAR model for drug binding to the A variant. Mol Pharm 1998;54:129-38
   PubMed Web of Science ®Google Scholar
• Kaliszan R, Nasal A, Turowski M. Binding site for basic drugs on alpha 1-acid glycoprotein as revealed by chemometric analysis of biochromatographic data. Biomed Chromatogr 1995;9:211-15
   PubMed Web of Science ®Google Scholar
• He XM, Carter DC. Atomic structure and chemistry of human serum albumin. Nature 1992;358:209-15
   PubMed Web of Science ®Google Scholar
• Zhu L, Yang F, Chen L, A new drug binding subsite on human serum albumin and drug-drug interaction studied by X-ray crystallography. J Struct Biol 2008;162:40-9
   PubMed Web of Science ®Google Scholar
• Lejon S, Cramera JF, Nordberg P. Structural basis for the binding of naproxen to human serum albumin in the presence of fatty acids and the GA module. Acta Cryst 2008;F64:64-9
   Google Scholar
• Almogren A, Furtado PB, Sun Z, Purification, properties and extended solution structure of the complex formed between human immunoglobulin A1 and human serum albumin by scattering and ultracentrifugation. J Mol Biol 2006;356:413-31
   PubMed Web of Science ®Google Scholar
• Curry S, Mandelkow H, Brick P, Franks N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat Struct Biol 1998;5:827-35
   PubMed Web of Science ®Google Scholar
• Sugio S, Kashima A, Mochizuki S, Crystal structure of human serum albumin at 2.5 Å resolution. Protein Eng 1999;12:439-46
   PubMedGoogle Scholar
• Bhattacharya AA, Grüne T, Curry S. Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J Mol Biol 2000;303:721-32
   PubMed Web of Science ®Google Scholar
• Bhattacharya AA, Curry S, Franks NP. Binding of the general anesthetics propofol and halothane to human serum albumin. J Biol Chem 2000;275:38731-8
   PubMed Web of Science ®Google Scholar
• Petitpas I, Grüne T, Bhattacharya AA, Curry S. Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids. J Mol Biol 2001;314:955-60
   PubMed Web of Science ®Google Scholar
• Zunszain PA, Ghuman J, Komatsu T, Crystal structural analysis of human serum albumin complexed with hemin and fatty acid. BMC Struct Biol 2003;3:6-14
   PubMedGoogle Scholar
• Wardell M, Wang Z, Ho JX, The atomic structure of human methemalbumin at 1.9 Å. Biochem Biophys Res Commun 2002;291:813-19
   PubMed Web of Science ®Google Scholar
• Yang F, Bian C, Zhu L, Effect of human serum albumin on drug metabolism: structural evidence of esterase activity of human serum albumin. J Struct Biol 2007;157:348-55
   PubMed Web of Science ®Google Scholar
• Zunszain PA, Ghuman J, McDonagh AF, Curry S. Crystallographic analysis of human serum albumin complexed with 4Z,15E-bilirubin-IXalpha. J Mol Biol 2008;381:394-406
   PubMed Web of Science ®Google Scholar
• Guo S, Shi X, Yang F, Structural basis of transport of lysophospholipids by human serum albumin. Biochem J 2009;423:23-30
   PubMed Web of Science ®Google Scholar
• Ryan AJ, Ghuman J, Zunszain PA, Structural basis of binding of fluorescent, site-specific dansylated amino acids to human serum albumin. J Struct Biol 2011;174:84-91
   PubMed Web of Science ®Google Scholar
• Hein KL, Kragh-Hansen U, Morth JP, Crystallographic analysis reveals a unique lidocaine binding site on human serum albumin. J Struct Biol 2010;171:353-60
   PubMed Web of Science ®Google Scholar
• Buttar D, Colclough N, Gerhardt S, A combined spectroscopic and crystallographic approach to probing drug–human serum albumin interactions. Bioorg Med Chem 2010;18:7486-96
   PubMed Web of Science ®Google Scholar
• Yamaguchi S, Aldini G, Ito S, Δ12-Prostaglandin J2 as a product and ligand of human serum albumin: formation of an unusual covalent adduct at his146. J Am Chem Soc 2010;132:824-32
   PubMed Web of Science ®Google Scholar
• Ryan AJ, Chung C-W, Curry S. Crystallographic analysis reveals the structural basis of the high-affinity binding of iophenoxic acid to human serum albumin. Bmc Struct Biol 2011;11:18-24
   PubMedGoogle Scholar
• He Y, Ning T, Xie T, Large-scale production of functional human serum albumin from transgenic rice seeds. Proc Natl Acad Sci USA 2011;108:19078-83
   PubMed Web of Science ®Google Scholar
• Yang F, Ma Z, Ma L, Human serum albumin-myristate-amantadine hydrochloride complex. Available from: http://www.rcsb.org/pdb/explore/explore.do?structureId=3uiv
   Google Scholar
• Luo Z, Shi X, Hu Q, Structural evidence of perfluorooctane sulfonate transport by human serum albumin. Chem Res Toxicol 2012;25:990-2
   PubMed Web of Science ®Google Scholar
• Wang Y, Luo Z, Shi X, A fluorescent fatty acid probe, DAUDA, selectively displaces two myristates bound in human serum albumin. Protein Sci 2011;20:2095-101
   PubMed Web of Science ®Google Scholar
• Mao H, Hajduk PJ, Craig R, Rational design of diflunisal analogues with reduced affinity for human serum albumin. J Am Chem Soc 2001;123:10429-35
   PubMed Web of Science ®Google Scholar
• Sheppard GS, Wang J, Kawai M, Discovery and optimization of anthranilic acid sulfonamides as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of albumin binding. J Med Chem 2006;49:3832-49
   PubMed Web of Science ®Google Scholar
• Lu Y, Feng Q, Cui F, Interaction of 3'-azido-3'-deamino daunorubicin with human serum albumin: investigation by fluorescence spectroscopy and molecular modeling methods. Bioorg Med Chem Lett 2010;20:6899-904
   PubMed Web of Science ®Google Scholar
• Wendt MD, Shen W, Kunzer A, Discovery and structure-activity relationship of antagonists of b-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo. J Med Chem 2006;49:1165-81
   PubMed Web of Science ®Google Scholar
• Keserü GM. A virtual high throughput screen for high affinity cytochrome P450cam substrates. Implications for in silico prediction of drug metabolism. J Comput Aided Mol Des 2001;15:649-57
   PubMed Web of Science ®Google Scholar
• Enyedy IJ, Egan WJ. Can we use docking and scoring for hit-to-lead optimization? J Comput Aided Mol Des 2008;22:161-8
   PubMed Web of Science ®Google Scholar
• Brandt T, Holzmann N, Muley L, Congeneric but still distinct: how closely related trypsin ligands exhibit different thermodynamic and structural properties. J Mol Biol 2011;405:1170-87
   PubMed Web of Science ®Google Scholar
• Gumede NJ, Singh P, Sabela MI, Experimental-like affinity constants and enantioselectivity estimates from flexible docking. J Chem Inf Model 2012;52:2754-9
   PubMed Web of Science ®Google Scholar
• Chen L, Chen X. Results of molecular docking as descriptors to predict human serum albumin binding affinity. J Mol Graph Model 2012;33:35-43
   PubMed Web of Science ®Google Scholar
• Kaliszan R. Structure and retention in chromatography: a chemometric approach. Harwood Academic Publishers, Amsterdam, The Netherlands; 1997
   Google Scholar
• Kaliszan R, Noctor TA, Wainer IW. Stereochemical aspects of benzodiazepine binding to human serum albumin. II. Quantitative relationships between structure and enantioselective retention in high performance liquid affinity chromatography. Mol Pharmacol 1992;42:512-17
   PubMed Web of Science ®Google Scholar
• Kaliszan R, Noctor TAG, Wainer IW. Quantitative structure-enantioselective retention relationships for the chromatography of 1,4-benzodiazepines on a human serum albumin based HPLC chiral stationary phase: an approach to the computational prediction of retention and enantioselectivity. Chromatographia 1992;33:546-50
   Web of Science ®Google Scholar
• Ashton DS, Beddell C, Ray AD, Valkó K. Quantitative structure-retention relationships of acyclovir esters using immobilised albumin high-performance liquid chromatography and reversed-phase high-performance liquid chromatography. J Chromatogr A 1995;707:367-72
   Web of Science ®Google Scholar
• Aureli L, Cruciani G, Cesta MC, Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach. J Med Chem 2005;48:2469-79
   PubMed Web of Science ®Google Scholar
• Milano Chemometrics and QSAR Research Group, Talete, Milano, Italy. Available from: http://www.disat.unimib.it/chm/Dragon.htm
   Google Scholar
• CODESSA PRO, University of Florida. Available from: http://www.codessa-pro.com/descriptors/index.htm
   Google Scholar
• Todeschini R, Consonni V. Handbook of molecular descriptors. Wiley, Weinheim; 2000
   Google Scholar
• Tropsha A, Gramatica P, Gombar VK. The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb Sci 2003;22:69-77
   Google Scholar
• Chirico N, Gramatica P. Real external predictivity of QSAR models. Part 2. New intercomparable thresholds for different validation criteria and the need for scatter plot inspection. J Chem Inf Model 2012;52:2044-58
   PubMed Web of Science ®Google Scholar
• Roy K, Mitra I, Kar S, Comparative studies on some metrics for external validation of QSPR models. J Chem Inf Model 2012;52:396-408
   PubMed Web of Science ®Google Scholar
• Stanforth RW, Kolossov E, Mirkin B. A measure of domain of applicability for QSAR modelling based on intelligent K-means clustering. QSAR Comb Sci 2007;26:837-44
   Google Scholar
• Hertzberg RP, Pope AJ. High-throughput screening: new technology for the 21st century. Curr Opin Chem Biol 2000;4:445-51
   PubMed Web of Science ®Google Scholar
• Rodgers SL, Davis AM, van de Waterbeemd H. Time-series QSAR analysis of human plasma protein binding. QSAR Comb Sci 2007;26:511-21
   Google Scholar
• Rodgers SL, Davis AM, Tomkinson NP, van de Waterbeemd H. Predictivity of simulated ADME AutoQSAR models over time data. Mol Inf 2011;30:256-66
   PubMed Web of Science ®Google Scholar
• Cartmell J, Enoch S, Krstajic D, Leahy DE. Automated QSPR through competitive workflow. J Comput Aided Mol Des 2005;19:821-33
   PubMed Web of Science ®Google Scholar
• Valkó K. Application of high-performance liquid chromatography based measurements of lipophilicity to model biological distribution. J Chromatogr A 2004;1037:299-310
   PubMed Web of Science ®Google Scholar
• Colmenarejo G. In silico prediction of drug-binding strengths to human serum albumin. Med Res Rev 2003;23:275-301
   PubMed Web of Science ®Google Scholar
• Wen Y, Liu H, Luan F, Gao Y. Application of quantitative structure–activity relationship to the determination of binding constant based on fluorescence quenching. J Luminescence 2011;131:126-33
   Web of Science ®Google Scholar
• Saiakhov RD, Stefan LR, Klopman G. Multiple computer-automated structure evaluation model of the plasma protein binding affinity of diverse drugs. Perspect Drug Discov Des 2000;19:133-55
   Google Scholar
• Klopman G. The MultiCASE program II. Baseline activity identification algorithm (BAIA). J Chem Inf Comput Sci 1998;38:78-81
   PubMedGoogle Scholar
• Colmenarejo G, Alvarez-Pedraglio A, Lavandera JL. Cheminformatic models to predict binding affinities to human serum albumin. J Med Chem 2001;44:4370-8
   PubMed Web of Science ®Google Scholar
• Hall LM, Lowell H, Kier LBJ. Modeling drug albumin binding affinity with E-state topological structure representation. Chem Inf Comput Sci 2003;43:2120-8
   PubMedGoogle Scholar
• Valkó K, Nunhuck S, Bevan C, Fast gradient HPLC method to Determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity. J Pharm Sci 2003;92:2236-48
   PubMed Web of Science ®Google Scholar
• Abraham MH, Chadha HS, Whiting GS, Mitchell RC. Hydrogen bonding. 32. An analysis of water-octanol and water-alkane partitioning and the delta log P parameter of Seiler. J Pharm Sci 1994;83:1085-100
   PubMed Web of Science ®Google Scholar
• Gunturi SB, Narayanan R, Khandelwal A. In silico ADME modelling 2: computational models to predict human serum albumin binding affinity using ant colony systems. Bioorg Med Chem 2006;14:4118-29
   PubMed Web of Science ®Google Scholar
• Deeb O, Hemmateenejad B. ANN-QSAR Model of drug-binding to human serum albumin. Chem Biol Drug Des 2007;70:19-29
   PubMed Web of Science ®Google Scholar
• Wichmann K, Diedenhofen M, Klamt A. Prediction of blood-brain partitioning and human serum albumin binding based on COSMO-RS sigma-moments. J Chem Inf Model 2007;47:228-33
   PubMed Web of Science ®Google Scholar
• Liu J, Yang L, Li Y, Constructing plasma protein binding model based on a combination of cluster analysis and 4D-fingerprint molecular similarity analyses. Bioorg Med Chem 2006;14:611-21
   PubMed Web of Science ®Google Scholar
• Votano JR, Parham M, Hall LM, QSAR modeling of human serum protein binding with several modeling techniques utilizing structure-information representation. J Med Chem 2006;49:7169-81
   PubMed Web of Science ®Google Scholar
• Hajduk PJ, Mendoza R, Petros AM, Ligand binding to domain-3 of human serum albumin: a chemometric analysis. J Comp Aided Mol Des 2003;17:93-102
   PubMed Web of Science ®Google Scholar
• Cruciani G, Pastor M, Clementi S. Handling information from 3D grid maps for QSAR studies. In: Gundertofte K, Jørgensen FE, editors. Molecular modeling and prediction of bioactivity. Kluwer Academic/Plenum Publishers, New York; 2000. p. 73-82
   Google Scholar
• Li H, Chen Z, Xu X, Predicting human plasma protein binding of drugs using plasma protein interaction QSAR analysis (PPI-QSAR). Biopharm Drug Dispos 2011;32:333-42
   PubMed Web of Science ®Google Scholar
• Estrada E, Uriarte E, Molina E, An integrated in silico analysis of drug-binding to human serum albumin. J Chem Inf Model 2006;46:2709-24
   PubMed Web of Science ®Google Scholar
• Zsila F, Bikadi Z, Malik D, Evaluation of drug–human serum albumin binding interactions with support vector machine aided online automated docking. Bioinformatics 2011;27:1806-13
   PubMed Web of Science ®Google Scholar